VITAL THERAPIES WKN: A2PHD4 ISIN: US4525EP1011 Kürzel: IMUX Forum: Aktien Thema: Hauptdiskussion

Also, kurzes Fazit: Finanzierung steht wieder. Sonst hat sich nichts geändert. Natürlich gut, dass da jemand an IMUX glaubt, so wie wir. Es bleibt alles möglich: Verstetigung des Kursanstieges oder ein nochmaliges Zusammenfallen wie bei einem Suflet. Interessant wird es leider erst 2025. Looooong….

Bitte stürz ab

Hoffe nachher nochmal über 2€

Bedeutet?

Quelle: stocktitan.net

NEW YORK, Jan. 5, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX) ("Immunic" or the "Company"), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced it has entered into a securities purchase agreement with select accredited investors to purchase shares of common stock (or pre-funded warrants in lieu thereof) in a three-tranche offering. The first tranche is an upfront payment of $80 million at $1.43 per share, which is expected to close on January 8, 2024, subject to customary closing conditions. The second tranche is a mandatory purchase of an additional $80 million of shares of common stock (or pre-funded warrants) at $1.716 per share, representing 120% of the first tranche purchase price and is conditioned on the announcement of phase 2b topline data for the Company's vidofludimus calcium (IMU-838) progressive multiple sclerosis clinical trial, volume weighted average share price levels, and minimum trading volumes. A third tranche, to occur no later than three years after the second tranche, provides for the issuance of $80 million of shares of common stock (or pre-funded warrants in lieu thereof) at the same price per share as the second tranche, but permits investors to fund their purchase obligations on a "cashless" or net settlement basis, which would reduce the proceeds to be raised in the financing. The third tranche is conditioned on the same volume weighted average share price levels and minimum trading volumes as the second tranche. Assuming that the second tranche is exercised, and depending on the extent to which the investors elect to fund the third tranche through a net settlement basis, total gross proceeds from the offering to the Company would be between $160 and $240 million.

Meine Alerts sind gerade alle gefallen. Was ist das denn…? Hält das überhaupt bis 15.30 h? Hat jemand vertiefende Infos?

Denkt dran Gewinne mitnehmen. Wird denke ich spätestens heute nachmittag Abverkäufe geben.

Niemand hat so viel Pech wie ich. Wäre ich investiert wäre der niemals so gestiegen....

Ihr seid alle Lucker

Ihr Lucker. Mit mir wäre der Anstieg bie passiert

Zug weg. Adios euch

Will rein

2€

Fast 2€

🤑